PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates through three lines of business: Medical Devices, Diagnostics, and Digital Health. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is focused on enhanced personalized cancer care through remote patient monitoring using implantable vascular access port with wireless communication combined with an oncologist-designed remote digital healthcare platform.
Símbolo de cotizaciónPAVMZ
Nombre de la empresaPAVmed Inc
Fecha de salida a bolsaJul 27, 2016
Director ejecutivoDr. Lishan Aklog, M.D.
Número de empleados39
Tipo de seguridadCompany Warrant
Fin del año fiscalJul 27
Dirección360 Madison Avenue
CiudadNEW YORK
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal10017
Teléfono12129494319
Sitio Webhttps://pavmed.com/
Símbolo de cotizaciónPAVMZ
Fecha de salida a bolsaJul 27, 2016
Director ejecutivoDr. Lishan Aklog, M.D.
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos